Stroke Transfer: Collateral Blood Flow, Not Time, Is Brain? (CME/CE)
(MedPage Today) -- Leptomeningeal collaterals crucial to maintaining ASPECTS during patient transfer
Conclusions: The 6-degree HDT revealed no adverse effects on the cardiovascular system, showing nonsignificant increment in the finger-tapping test (representative of motor speed and performance) and nonsignificant reduction in the digit backward span test (representative of spatial memory).
We report on a patient who developed massive gastrointestinal hemorrhage related to the use of fluoxetine in combination with aspirin and clopidogrel. A 58-year-old man was admitted with a posterior circulation infarct with significant weakness in all four limbs and dysarthria. Aspirin and clopidogrel were started. Fluoxetine was started for pharmacological neurostimulation to promote motor recovery and for low mood. He developed gastrointestinal hemorrhage a week after fluoxetine was started. Fluoxetine was suspended and investigations failed to reveal the source of the bleeding. He was then restarted on fluoxetine along ...
Abstract Background: Frailty is identified as a major predictor of adverse outcomes in older surgical patients. However, the outcomes in pre-frail patients after cardiovascular surgery remain unknown. Objective: To investigate the main outcomes (length of stay, mechanical ventilation time, stroke and in-hospital death) in pre-frail patients in comparison with no-frail patients after cardiovascular surgery. Methods: 221 patients over 65 years old, with established diagnosis of myocardial infarction or valve disease were enrolled. Patients were evaluated by Clinical Frailty Score (CFS) before surgery and allocated into 2 gro...
Intensive lowering of systolic blood pressure to levels below 120 mm Hg does not increase the risk for stroke, even with lower mean arterial pressure levels, new research shows.Medscape Medical News
Life span about three years less than for whites, heart association statement says
(MedPage Today) -- CV disease accounts for large portion of health disparities
(MedPage Today) -- But trajectory of increasing disability not as steep after MI
Medtronic (NYSE:MDT) said today it launched a pivotal trial of its Intrepid transcatheter mitral valve replacement system after winning FDA investigational device exemption for the device. The 1st patient in the trial was enrolled at Milwaukee’s Aurora St. Luke’s Medical Center, the Fridley, Minn.-based company said. The Apollo trial is slated to enroll up to 1,200 patients with severe, symptomatic mitral valve regurgitation into 2 cohorts with a primary endpoint of composite of all-cause mortality, all-stroke, reoperation or reintervention and cardiovascular hospitalization at 1 year. Secondary endpoints ...
Conditions: Stroke; Acute Stroke; Ischemic Stroke; Hemorrhagic Stroke; Subarachnoid Hemorrhage; Cerebral Ischemia; Cerebral Infarction; Cerebral Stroke; Cerebral Vascular Accident Intervention: Sponsors: University of California, San Francisco; SanBio, Inc.; Sunovion Recruiting
Conditions: Improve Hand Function; Stroke; Upper Extremity; Hemiparesis; Cerebrovascular Accident; Stroke Rehabilitation; Sensory; Sensation Interventions: Device: TheraBracelet & Stimulation; Device: TheraBracelet & Sham Sponsors: TheraBracelet, Inc.; Medical University of South Carolina Active, not recruiting